Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd is pleased to announce the successful dosing of 15 patients in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. RECCE® 327 topical gel (R327G) has shown promising antibacterial effects across a broad range of human infections, with patients safely tolerating the treatment. This marks a significant step in addressing unmet medical needs in areas such as diabetic foot infections and wound infections.

The Phase II clinical trial, designed to evaluate the efficacy and systemic absorption of R327G, is on track to enroll 30 participants by the end of the year. The expansion of study locations in NSW and Victoria aims to broaden access to this innovative treatment. CEO James Graham expressed excitement over the potential impact of R327G in the growing global healthcare demand for effective antimicrobials.

Recce remains committed to developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs, addressing critical global health challenges.

Recce Pharmaceuticals Ltd is pleased to announce the successful dosing of 15 patients in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. RECCE® 327 topical gel (R327G) has shown promising antibacterial effects across a broad range of human infections, with patients safely tolerating the treatment. This marks a significant step in addressing unmet medical needs in areas such as diabetic foot infections and wound infections.<br/><br/>The Phase II clinical trial, designed to evaluate the efficacy and systemic absorption of R327G, is on track to enroll 30 participants by the end of the year. The expansion of study locations in NSW and Victoria aims to broaden access to this innovative treatment. CEO James Graham expressed excitement over the potential impact of R327G in the growing global healthcare demand for effective antimicrobials.<br/><br/>Investors are invited to inquire about this milestone clinical trial progress and the potential market opportunities it presents for Recce Pharmaceuticals. We remain committed to developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs and emerging viral pathogens, addressing critical global health challenges.

Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

Announcement summary